We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bitter pill

16 August 2012 By Reynolds Holding

Pfizer is the latest company to sustain its patent over a medication by handing a rival exclusive, but delayed, rights to a generic version. That’s an anticompetitive quid pro quo, even if cash didn’t change hands. A U.S. court can protect consumers’ wallets by saying so.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)